What’s Driving Apellis Pharmaceuticals Stock Down?

Apellis Pharmaceuticals ( (APLS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.

Apellis Pharmaceuticals’ stock is experiencing a downward trend due to negative sentiment from recent insider selling activities, including sales by the Chief Medical Officer. This has led to varied analyst opinions with Piper Sandler maintaining a Hold rating and setting a price target of $32.00, slightly below its last close of $33.00. While the overall analyst consensus remains a Moderate Buy with an average price target of $46.40, RBC Capital also holds a Hold rating but has adjusted its target to $26.00, up from $24.00, reflecting cautious market conditions.

More about Apellis Pharmaceuticals

YTD Price Performance: -0.48%

Average Trading Volume: 3,094,285

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $4.1B

For further insights into APLS stock on TipRanks’ Stock Analysis page.

See more of today’s top stock gainers and losers.